ImvivaBio’s off-the-shelf CD19/BCMA CAR-T cell therapy CTA313 kept 88% of evaluable patients with refractory lupus in DORIS remission at Month 12, according to longer-term phase 1 data presented at ACR Convergence 2026.
|Articles|May 3, 2019
Freeline Installs Pall System at Gene Therapy Facility
Author(s)BioPharm International Editors
In collaboration with Pall Corportion, biotech company Freeline completed the first full-scale run at its newly commissioned, GMP gene-therapy manufacturing facility in the UK.
Advertisement
On April 29, 2019, Pall Corporation, a manufacturer of biopharmaceutical processing technology, and Freeline, a biotech company focused on developing gene therapies for chronic systemic diseases, announced the completion of the first full-scale run in Freeline’s newly commissioned GMP facility located at the Cell and Gene Therapy Catapult facility in Stevenage, UK. The Freeline proprietary adeno-associated virus (AAV) manufacturing platform uses Pall’s iCELLis bioreactor system to produce AAV gene therapy vectors. The two companies will extend their partnership to accelerate in-house production of Freeline products.
With the scale and automation provided by the iCELLis bioreactor, the adherent cell culture format used in the new system allows for the production of the AAV virus in a way that maximizes quality and yield, Pall reports. The manufacturing process at the Freeline facility at Catapult was achieved in collaboration with Pall through integrated modeling processes and design features. The platform is used at three locations as Freeline continues to expand its manufacturing capabilities.
“This is an important step forward for Freeline as we look to manufacture product for clinical trials with a commercially ready manufacturing platform in order to ensure the fastest possible development towards licensure,” said Jan Thirkettle, chief development officer of Freeline, in a company press release. “Our collaboration with Pall has been critical to our progress and we are excited to be working with them as we prepare for commercial supply and further development of our proprietary AAV manufacturing technology.”
“The iCELLis bioreactor system, coupled with Pall’s Accelerator [p]rocess [d]evelopment [s]ervices, helped deliver a robust and scalable process for Freeline to reduce time to market. We are proud that our iCELLis technology now enables the development of Freeline’s life-changing therapies,” said Roel Gordijn, vice-president, integrated solutions at Pall, in the release. “Pall continues to invest in its iCELLis technology, ensuring that it is available to the rapidly growing gene therapy industry.”
Source:
Advertisement
Related to this article
FDA’s draft framework would let sponsors add patient-specific genome editing variants to an approved BLA using in vitro data. Here is what the guidance proposes, what evidence it asks for, and what remains unresolved.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
UCB will use Cradle’s AI-driven protein design platform in selected discovery projects, from hit generation through preclinical readiness, expanding its digital antibody engineering program.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
4
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
5